Moderna's mRNA flu shot earns FDA approval after rollercoaster review

Moderna's mRNA flu vaccine, mFLUSIVA, received FDA approval for use in adults ages 50 and older. The approval applies to all adults within that age group. No additional details about the approval timeline or clinical trial data were provided.

Next story